Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005841 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00005841 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 15 participants.
The verdict
NCT00005841, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma that has been completely removed during surgery.
Interventions
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL MART-1 antigen
- BIOLOGICAL tyrosinase peptide
- BIOLOGICAL progenipoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-06 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005841
The ClinicalTrials.gov registry entry for NCT00005841 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which incomplete Freund's adjuvant is the first listed.
NCT00005841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005841 about?
NCT00005841 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of vac...
What is the current status of trial NCT00005841?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2000-06. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00005841?
The interventions under investigation include: incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), MART-1 antigen (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL), progenipoietin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005841?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.